Woman's death exposes need for ME care reforms
This commitment follows the death of 27-year-old Maeve Boothby-O'Neill, who died from severe malnutrition due to ME, prompting a coroner to highlight systemic issues.
The inquest into Miss Boothby-O'Neill's death revealed a critical lack of specialist beds, 'extremely limited' training for doctors, and insufficient funding for ME/CFS research and treatment.
The Department of Health and Social Care (DHSC) is set to publish a new plan outlining steps to improve patient care, including new training for NHS staff and investment in research.
While public health minister Ashley Dalton welcomed the plan, the charity Action for ME criticised it for not going 'far enough,' advocating for a dedicated, funded research hub to find treatments and cures.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Independent
28 minutes ago
- The Independent
This new SPF from ESPA hydrates, protects and leaves skin naturally radiant with 92% of users agreeing
There's something quietly reassuring about a solid skincare routine, especially when it doesn't require a dozen complicated steps or leave you feeling slick. Still, for many of us SPF is the step that gets forgotten, skipped or reserved for holidays abroad. And who can blame us? Traditional sunscreens can feel chalky, greasy or leave behind a ghostly, stubborn white cast. The thing is: protecting your skin isn't just about beach days. With UV rays, blue light from screens and urban pollution all contributing to premature ageing, SPF really is an everyday essential – whether you're sitting on a sun-drenched patio or just replying to emails indoors. Enter ESPA's new Protect & Brighten Daily Skin Shield SPF 50 (£40, Designed to slot seamlessly into your morning routine, it promises comfortable and lightweight protection, and leaves your skin with a natural luminosity that looks fresh, not filtered. In fact, 92 per cent of users said it gave their skin a visible dewy glow. For those concerned about signs of ageing, or simply wanting to maintain a youthful-looking complexion, this may well be the SPF you've been searching for. So, what makes it stand out in a sea of sun protection? And what's behind these glow-giving claims? Let's take a look. More than sun care Unlike heavy-duty sunscreen sprays that sit on top of the skin, ESPA's Skin Shield is formulated like a luxurious moisturiser that just so happens to include SPF 50. It's powered by hydrating hyaluronic acid, antioxidant-rich beta carotene and Chinese butterfly bush extract, which help to defend against UV rays, blue light and pollution. Together, they offer more than just sun protection: they soothe, hydrate and actively help to reduce the visible signs of ageing. From fine lines to sun spots and uneven tone, the daily aggressors this product guards against are relevant year-round – not just during a heatwave. And because the texture is so lightweight and non-greasy, it layers easily over your existing moisturiser or under make-up (if you're wearing any), without pilling or feeling cakey. A 3-in-1 primer, protector and glow-booster The real beauty of ESPA's Skin Shield lies in its finish. Fast-absorbing and silky, it gives skin a subtle radiance that leaves you looking lit-from-within, naturally and without the strobe effect of a highlighter or shimmer. There's no white cast, no stickiness or even the sensation that you're wearing anything. It's the kind of multi-tasker we look to in the summer months: simplifying your morning routine but sacrificing neither sun protection nor skin smoothing. You can use it as your final skincare step, a smoothing primer or the one thing you slap on if you're running out the door. According to user trials, 96 per cent agreed their skin looked brighter after just two weeks of use and 83 per cent said fine lines and wrinkles appeared softened. For a no-makeup-makeup look, this one's doing the heavy lifting. For all skin types and every kind of day One of the biggest pain points with SPF is inclusivity, and ESPA has paid attention here. Skin Shield is wearable on all tones and textures, from dry and sensitive to oily or blemish-prone. It doesn't clog, flake or fight your base, and it's as comfortable for long hikes as it is for commuting. Add in the fact that you're getting broad-spectrum UVA/UVB coverage and oxidative stress protection in one simple step, and it starts to feel less like a luxury and more like a non-negotiable. Plus, with 20 per cent off (was £50, now £40, it's a timely excuse to elevate your skincare essentials before the seasons shift.
The Independent
28 minutes ago
- The Independent
Researchers find milk type that increases risk of heart disease and death
A 33-year study conducted in Norway has investigated the long-term health impacts of consuming full-fat versus low-fat milk. Researchers analysed health data from 73,860 individuals, finding that the fat content of milk influenced the risk of death from heart disease. The study revealed that individuals who consumed full-fat milk had a higher mortality risk compared to those who drank low-fat milk. Specifically, consuming low-fat milk was linked to an 11 per cent lower overall mortality risk and a 7 per cent reduced risk of cardiovascular disease compared to whole milk. These findings support current NHS health advice, which cautions against high intake of saturated fat found in full-fat dairy due to its link to increased cholesterol and heart disease risk.
BBC News
29 minutes ago
- BBC News
Shrewsbury cancer charity ready for clinical trials of new drug
A Shropshire charity says it is ready to start clinical trials on a new drug to treat lung the charity Brightwater Research was formed in 2019, its founders have spent 15 years developing the drug Valoxydin, and said the results of initial testing had been manager David Crane said the drug was designed to prevent tumours spreading around the charity is currently seeking funding to fully develop the drug so it can eventually be used to treat patients. Decisions about which medicines are made available on the NHS are made by different organisations in England, Wales and are usuaully based on factors, including the evidence available about a drug and the length by which it could extend patients' from experts and public involvement is also considered. Mr Crane said Valoxydin was an anti-metastatic drug which targeted the formation of secondary tumours – also known as metastases - in the body and stopped the primary cancer from showed the drug could potentially reduce the spread of lung cancer by approximately 80% in animal models, he trustee Ted Youngman, whose father died with lung and brain cancer 15 years ago, said from the initial theory about how the treatment might work, they had begun to experiment with the drug in a petri dish and had gone through more than 50 variations to reach the point it was now at. 'Tremendous' "There's a lot of work still to go, but this is tremendous," Mr Youngman added: "It's much easier to stop [cancer] from spreading than it is to treat it once it's already spread."That's the approach we're taking, which we think is a bit different from other treatments before now."The charity's founders believe it might be possible the drug could be developed for use in the treatment of liver, kidney and bowel cancer, but added a significant amount of additional funding would be needed for further with potential large-scale backers had already begun, Mr Crane said the process could take two to three years, at which point it might be ready for consideration by the drug would be taken as a pill, which would mean it was relatively easy to administer to Crane said the drug would need to be taken daily for the rest of the patient's life – or until another solution is discovered. Follow BBC Shropshire on BBC Sounds, Facebook, X and Instagram.
